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a b s t r a c t
Pyoderma gangrenosum is a chronic inflammatory dermatosis, which is associated with 
non-infectious systemic diseases such as rheumatoid arthritis and inflammatory bowel 
disease. It is more common in adults and may present with four distinct clinical forms, all 
leading to ulceration of the skin affected. Its diagnosis is clinical and demands exclusion of 
other causes. Treatment should be performed with local care and systemic therapy.
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r e s u m o
O pioderma gangrenoso é uma dermatose inflamatória crônica, que se associa a doenças 
sistêmicas como a artrite reumatoide. É mais comum em adultos e pode se apresentar com 
quatro formas clínicas, todas levando à ulceração da pele acometida. Seu diagnóstico é clíni-
co e de exclusão. O tratamento deve ser realizado com cuidados locais e terapia sistêmica.
© 2014 Sociedade Brasileira de Reumatologia. Publicado por Elsevier Editora Ltda. 
Todos os direitos reservados.
Introduction
Pyoderma gangrenosum (PG) was first described over 70 years 
ago by Brunstinge O’Larry.1-3 This is a relatively infrequent, non-
infectious, idiopathic, chronic, relapsing inflammatory derma-
tosis, with a local destructive character, usually associated 
with other local or systemic diseases.4 It is more common in 
adults, but children can also be rarely affected.2 The most af-
fected age group is from 25 to 55 years old, and this disease 
is more common in women. The aetiology of PG is poorly un-
derstood, although it appears to be an immune-mediated cu-
taneous damage. Neutrophil dysfunction, especially defects in 
chemotaxis, has been suggested as a possible cause of PG.1,2,4
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PG shows involvement predominantly of the lower limbs, 
but it may also affect the trunk, abdomen and face.2 Clini-
cally, the presence of hemorrhagic pustules, painful nodules 
or multiple vesicopustules are observed. These lesions evolve 
into destructive ulcers that grow centrifugally with slightly 
elevated, violaceous, sharply delineated, excavated edges 
presenting a necrotic center with presence of blood, pus and 
granulation tissue.2,3,5-7
There are four different clinical forms of PG.4,8 The ulcer-
ative form is the most frequent and corresponds to the clas-
sical clinical picture, usually associated with inflammatory 
bowel disease (IBD) and rheumatoid arthritis (RA). The pus-
tular form is characterized by painful pustules with an ery-
thematous halo, usually occurring in exacerbations of IBD.3 
The bullous form presents with superficial hemorrhagic blis-
ters that often leave scars, being associated with myeloprolif-
erative disease. The vegetative form presents as a superficial, 
painless, solitary ulceration not associated with systemic dis-
ease.5,8 The histopathology is nonspecific, and a lymphocytic 
vasculitis is found at the erythematous edge of the lesion, be-
sides the presence of polymorphonuclear-rich abscesses.5,6,8 
Usually, the clinical diagnosis is obtained by exclusion.4,5,6
RA is a systemic autoimmune inflammatory disease char-
acterized by a chronic, symmetric and erosive polyarthritis, 
especially of small joints. Besides the joint picture, RA can 
present extra-articular symptoms, including cutaneous man-
ifestations such as skin ulcers, rheumatoid nodules, vasculitis 
and PG necrotic lesions. Here we report a case of a patient 
with long-standing RA and poor adherence to treatment, who 
showed extensive necrotic ulcerated skin lesions character-
istic of PG.
Description of the case 
Patient with 40 years old, female, Caucasian, with a history of 
RA for 10 years. Two months ago was affected by erythema-
tous nodules on her left thigh and buttock, which progressed 
to ulcerations and extensive ulcer formation with more than 
10 cm in diameter. This clinical picture began shortly after her 
abruptly stopping the use of oral corticosteroids. The patient 
used disease-modifying drugs (DMDs) irregularly, discontinu-
ing the use of methotrexate for about two years. On physi-
cal examination, well-delimitated necrotic ulcerations with 
violaceous excavated edges and erythematous-violaceous 
halos were noted (Fig. 1). In addition, joint deformities com-
patible with ulnar deviation and swan neck and buttonhole 
fingers were seen. A skin biopsy revealed inflammation with 
neutrophilic vasculitis and fibrinoid necrosis of the vascular 
wall suggestive of PG (Fig. 2). Cultures for bacteria and fungi 
revealed no growth of microorganisms. Lab tests, including 
serology for hepatitis B, hepatitis C, anti-HIV and proteino-
gram were all normal, except by an increase in inflammatory 
markers and a high titre for rheumatoid factor. Radiological 
studies of hands and feet showed bone erosions in the proxi-
mal interphalangeal, metacarpophalangeal and metatarso-
phalangeal joints. The initial treatment was prednisone 1 
mg/kg /day PO in divided doses at intervals of 8 hours, with 
methotrexate 10 mg/week PO that was rapidly stepped up to 
25 mg/week SC. The patient underwent weekly reviews and 
daily dressings, obtaining an excellent clinical outcome with 
resolution of the lesions in approximately 3 months (Fig. 3).
Discussion
About 50% of cases of PG occur concomitantly with other dis-
ease, particularly IBD, RA, myeloproliferative diseases, hepa-
titis B and C, acquired immunodeficiency syndrome (AIDS), 
systemic lupus erythematosus, psoriasis and reactive ar-
thropathies.1,3,4,9 The other 50% of cases of PG occur in isola-
tion.1,4,5,8 The association with RA can occur in up to 37% of 
patients with PG and its appearance is more common after 
the onset of arthritis. Usually, patients with PG are positive 
for rheumatoid factor, and a common radiographic finding is 
the presence of erosions. RA affects women twice as often as 
men, and its incidence increases with age. When this disease 
involves other organs, the morbidity and disease severity are 
Fig. 1 – Ulcerated lesion with eritemato-violaceous 
escavated borders and center with necrotic areas on the 
front of the left thigh.
Fig. 2 – Skin biopsy of the lesion with neutrofilic vasculitis 
and fibrinoid necrosis (HE, 20x).
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more expressive, which may reduce the life expectancy in 
five to 10 years. The diagnosis depends on a combination of 
a number of clinical symptoms and signs, and on laboratory 
and radiographic findings. The patient described had RA for 
10 years and pursued an irregular treatment, which precipi-
tated the development of lesions of PG.
Some diagnostic criteria for PG have been proposed, but 
until now with no validation. The criteria of Su et al. (2004) 
are divided into major (rapid progression of a painful ulcer 
with irregular and violaceous edges and with exclusion of 
other causes of cutaneous ulcers) and minor (history sugges-
tive of pathergy, systemic diseases associated with PG, histo-
pathology findings of sterile dermal neutrophilia, inflamma-
tory infiltrate and lymphocytic vasculitis, and rapid response 
to treatment with corticosteroids) criteria.2,3,7 The diagnosis 
would be established with two major criteria and one minor 
criterion.9 The patient cited in this report had, as major cri-
teria, the fast progression of a painful ulcer with irregular 
and violaceous edges and the exclusion of other causes of 
cutaneous ulcers; and, as minor criteria, diseases associated 
with systemic PG, histopathology presenting sterile dermal 
neutrophilia, inflammatory infiltrate and lymphocytic vas-
culitis, and a fast response to treatment with corticosteroids. 
It should be mandatory to obtain cultures for fungi and bac-
teria and routine haematological and biochemical workup.7 
The clinical and pathological findings and the evolution of 
the lesions of PG are important for the establishment of the 
diagnosis, but its basis is the exclusion of other diseases, 
especially infectious diseases, autoimmune disorders and 
malignancies.
The histopathology findings are not specific to PG and have 
variable aspects, depending on the biopsy site and duration of 
the disease, but it is essential to exclude other diagnoses.2 The 
differential diagnoses are vascular occlusions, stasis, vascu-
litis, malignancies, infections, aggression by physical agents, 
drug skin eruptions, cutaneous Crohn’s disease and ulcerated 
necrobiosis lipoidica.2
The evolution of PG is often chronic, with frequent recur-
rences, sometimes related to traumatic processes (pathergy 
phenomenon).3,5 Pathergy is defined as the development of a 
new inflammatory lesion in the trauma area. Even when min-
imal, the occurrence of trauma in a condition of pathergy may 
be followed by a progressive destruction of healthy skin. This 
phenomenon has been reported in 25% of patients with PG.
The management of PG includes topical care and local 
and systemic therapy. Daily wet dressings with petrolatum 
(to prevent trauma to the underlying tissue during removal) 
and infection control are essential for treatment of the ul-
cers. Surgical debridement should be avoided.2 Cultures of 
secretions may be positive for bacterial infection, but usu-
ally this results only in tissue colonization.7 Topical therapy 
is useful in some cases and the successful use of tacrolimus, 
pimecrolimus and potent topical corticosteroids have been 
reported.2,3 Initially, the systemic care consists of high doses 
of corticosteroids (1-2 mg/kg), aiming a quick response.8 The 
clinical improvement may take months; in some patients, im-
munomodulatory or immunosuppressive drugs must be add-
ed.9 The most commonly used medications are clofazimine, 
dapsone, thalidomide, methotrexate, cyclosporine, azathio-
prine, cyclophosphamide and mycophenolate mofetil.1,2,4-8 
Generally, these drugs are administered in association with 
corticosteroids, to reduce their dose and also in an attempt to 
control refractory cases.1,7 In refractory cases of PG, biological 
agents, such as anti-TNF alpha and fusion proteins, are used.7 
Recently, reports have been published demonstrating that in 
patients with neutrophilic dermatosis, an overproduction of 
TNF-alpha occurs. This is a proinflammatory cytokine which, 
together with IL-6, is associated with idiopathic forms of PG. 
With early institution of an aggressive treatment, one can de-
crease pain and prevent extensive scarring.5 In the literature, 
it was suggested that the severity of the associated disease 
is a factor that influences the prognosis of PG. In most cases, 
the effective treatment of the associated disease leads to im-
provement or complete remission of PG. 
Interestingly, although the global treatment of RA has 
evolved over the last decades, the prevalence of extra-artic-
ular manifestations has remained relatively constant. It is 
known that patients with PG in association with RA are more 
refractory to treatment than patients without arthritis.2 In 
this study, we present a case of PG associated with RA and 
triggered by an irregular treatment of the latter condition. We 
also demonstrate the severity of PG injuries and the optimal 
response after the implementation of treatment with cortico-
steroids and RA-modifying drugs.
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